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 The retina-specific ABC transporter, 
ABCA4, is essential for transport of all-trans 
retinal from the rod outer segment discs in the 
retina and is known to be associated with a 
broad range of inherited retinal diseases 
including, Stargardt disease (STGD), autosomal 
recessive cone rod dystrophy (arCRD) and 
fundus flavimaculatus (FFM). A unique feature 
of the ABCA subfamily of ABC transporters is 
the presence of highly conserved, long 
extracellular loops or domains (ECDs) with 
unknown function. The high degree of sequence 
conservation and mapped disease associated 
mutations in these domains suggest an 
important physiological significance.  
Conformational analysis using circular dichoric 
spectroscopy of purified, recombinant ECD2 
protein demonstrated that it has an ordered 
and stable structure comprised of 27±3% α-
helix, 20±3% β-pleated sheet, and 53±3% coil.  
Significant conformational changes were 
observed in disease-associated mutant proteins.  
Using intrinsic tryptophan fluorescence 
emission spectrum of ECD2 polypeptide, we 
have demonstrated that this domain specifically 
interacts with all-trans retinal with a Kd of 1.3 x 
10-7 M.  Furthermore, the retinal interaction 
appeared specific for the all-trans isomer, and 
was directly measurable through fluorescence 
anisotropy analysis of all-trans retinal.  This 
interaction was impaired in mutant ECD2 
proteins. In summary, our results demonstrate 
that the three macular degeneration-associated 
mutations lead to significant changes in the 
secondary structure of the ECD2 domain of 
ABCA4, as well as in its interaction with all-
trans-retinal. 
 
 ABC transporters are required for 
transport of a wide variety of hydrophobic 
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substances across cellular membranes, including 
drugs (1-3), lipids (4-6), metabolites, peptides (7), 
and steroids (2).  Typically, eukaryotic ABC 
proteins are comprised of two tandem sets of six 
transmembrane helices followed by a Walker type 
A and a type B nucleotide-binding motif (8). To 
date, 48 members of the human ABC transporter 
family have been identified, which, based on 
sequence homology, have been divided into seven 
subfamilies, ABCA through ABCG (2-3,9). 
 A retina specific variant of the ABCA 
subfamily, the ABCA4 gene product (ABCR) was 
first described as the bovine and Xenopus Rim 
proteins identified in the rims of the rod outer 
segment (ROS) discs (10-11). Mutations in the 
ABCA4 gene appear to lead to defects in the 
energy-dependent transport of all-trans retinal and 
lead to the accumulation of cytotoxic lipofuscin 
fluorophores in the retinal pigment epithelium 
characteristic of the diseases such as Stargardt 
disease (STGD), fundus flavimaculatus (FFM) and 
autosomal recessive cone-rod-dystrophy (arCRD), 
as well as increased susceptibility to age-related 
macular degeneration (AMD) (12-20).  Although 
ultimately these diseases await the promise of a 
cure through gene therapy (21-22), current 
treatments have been directed towards slowing the 
progression of the disease. Consequently, 
understanding how genetic mutations lead to 
retinal degeneration is critical for the development 
of experimental therapies. 
Studies in several laboratories and the 
establishment of ABCA4 screening consortiums 
have aided in the identification of over 500 
mutations in ABCA4 gene that are associated with 
a plethora of visual diseases.  A genotyping 
microarray chip has been developed for the 
ABCA4 gene which can robustly identify >98% of 
the existing mutations (23). Disease-associated 
ABCA4 alleles have shown an extraordinary 
genetic heterogeneity.  Some of these mutations 
map to the nucleotide binding domains (NBDs), 
suggesting that the underlying defect has a basis in 
nucleotide hydrolysis and/or aspects of energy 
transduction related to transport. However, the fact 
that ABCA4 mutations occur throughout the entire 
open reading frame, suggest that defects in ATP 
hydrolysis only are one of the causes of these 
diseases.  At present, the biochemical basis of 
functional defects due to mutations in domains 
other than the NBDs remain refractory to 
biochemical analysis, primarily because these 
domains lack any known enzymatic function. 
 Structural topology varies significantly 
between the eight subclasses of ABC transporters.  
In the ABCA subfamily each half transporter 
contains a transmembrane domain (TMD) 
comprised of six membrane spanning units, 
followed by a cytoplasmic or soluble domain.  In 
addition, each ABCA half transporter possesses a 
large extracellular loop, which is characteristic of 
this subfamily. In the case of ABCA4, several 
models of membrane topology have been proposed 
based on hydropathy profiles, and experimental 
data supports the notion that two large 
extracellular domains (ECDs) are present (24). 
The EC loops project from TMD1 for ECD1 and 
from TMD7 for ECD2; they represent 
significantly large polypeptide domains, with 603 
residues for ECD1 (aa 43–646) and 285 residues 
for ECD2 (aa 1395–1680).  The high degree of 
sequence conservation observed in the ECDs of 
vertebrate ABCA4 proteins suggests an important 
physiological significance (20,25).   
 In the absence of any known enzymatic or 
functional motif, it has been difficult to assess the 
significance of disease-associated mutations in the 
ECD domains of ABCA4. Expression and 
characterization of individual functional domains 
has been demonstrated to be a viable approach 
utilized by several laboratories working with other 
ABC proteins, such as the MDR1 and CFTR 
transporters (26-29). ABCA4 is a particularly 
large membrane protein (~220 kDa), which is 
fairly unstable as a recombinant whole molecule.  
Consequently, systematic analysis of the structure 
and function of each individual domain in 
recombinant form is a highly viable and specific 
approach, as demonstrated by our previous studies 
with the NBD1/NBD2 domains of ABCA4.  
Previously, we were able to delineate the structural 
and functional specificities of the individual 
nucleotide binding domains which would not have 
been possible using the full-length ABCA4 protein 
(30-32). 
  Fluorescence and CD spectroscopic 
methodologies have been utilized as valuable tools 
for the characterization of structure and function 
of a variety of proteins including ABC transporters 
(33-35). In this report we have employed these 
techniques to elucidate the structural features and 
functional properties of the second extracellular 
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loop of ABCA4 as well as to delineate the effects 
of disease-associated mutations in the ECD2 
domain.  
   
EXPERIMENTAL PROCEDURES 
 
Nucleic Acids, Enzymes, and Other Reagents. The 
pRK5 plasmid containing the full-length, wild-
type cDNA of the human ABCA4 gene was 
obtained as a generous gift from Drs. J. Nathans 
and Michael Dean of Johns Hopkins University 
(Baltimore, MD) and NCBI (Frederick, MD) 
respectively. The T7 expression system vector 
pET30b, Bug Buster protein extraction reagent, 
Benzonase nuclease and the S-protein agarose 
affinity resin were from Novagen (EMD Sciences; 
Briggstown, NJ). All-trans retinal was from 
Sigma/Aldrich (St. Louis, MO) while 11-cis 
retinal was synthesized by Toronto Research 
Chemicals, Canada. 
Buffers -- Buffer A was 20 mM Tris-HCl (pH 8.0), 
100 mM NaCl, 2 mM dithiothreitol, and 15% (v/v) 
glycerol. Buffer B contained 20 mM Tris-HCl (pH 
7.5), 1 mM MgCl2, 50 mM NaCl, 5% glycerol, and 
0.01% Nonidet P-40.  Buffer C was 6 M guanidine 
hydrochloride, 0.1 M Tris-HCl (pH 8.0), and 
2 mM EDTA. Buffer D contained 0.1 M Tris-HCl 
(pH 8.0), 0.5 M L-arginine, and 2 mM EDTA. 
Buffer E contained 10 mM NaPO4 (pH 7.4), 
100 mM NaCl, and 2 mM dithiothreitol.   
Design and Cloning of the Construct Containing 
ECD2. The ECD2 construct was amplified from 
full-length ABCA4 cDNA and cloned into 
pET30b T7-expression vector (EMD Sciences; 
Briggstown, NJ) using standard recombinant DNA 
technology (36).  This domain corresponds to a 
31.8 kDa (285 aa) polypeptide.  The cloning was 
designed such that the polypeptide was produced 
as a S-tagged fusion protein, leading to a predicted 
mass of 34.4 kDa for the recombinant ECD2.  For 
subsequent recombinant protein expression, the 
plasmid was used to transform E. coli strain BL21-
CodonPlus(DE3)-RILP competent cells 
(Stratagene, La Jolla, CA).  
In Vitro Site-directed Mutagenesis of the ECD2 
Construct.  Site-directed mutagenesis was carried 
out using a PCR based mutagenesis kit 
(Stratagene, La Jolla, CA) (32) and the pET30-
ECD2 plasmid as template.  The complementary 
oligonucleotides used as mutagenic primers to 
generate the mutant ECD2 proteins as detailed in 
Table 1.  The authenticity of the mutations and the 
absence of other fortuitous mutations were 
confirmed by DNA sequencing carried out by 
Eurofins MWG/Operon (Huntsville, AL). 
Over Expression of  pET30b-ECD2 in E. coli. E. 
coli cells (strain BL21-CodonPlus(DE3)-RILP; 
Stratagene; LaJolla, CA) harboring pET30b-ECD2 
plasmid were used to produce the recombinant 
ECD2 polypeptide following the manufacturer’s 
instructions.  The expressed recombinant 
polypeptide appeared to be of the anticipated size 
(34 kDa), as determined by SDS−PAGE (Fig. 3A).  
Extraction and Purification of Recombinant ECD2 
Proteins—Extraction and purification of wild-type 
ECD2 protein carrying the S-tag using 
immobilized S-protein agarose affinity resin 
(EMD Chemicals; Gibbstown, NJ) following the 
manufacturer’s recommendations as previously 
described (30).  
Purification of ECD2 Polypeptide from 
Solubilized Inclusion Bodies.  Introduction of 
mutations into wild-type ECD2 polypeptide 
appeared to decrease the solubility of the 
expressed proteins as determined by SDS-PAGE 
and Western blot procedure (data not shown).  
Consequently, we explored the extraction of 
recombinant proteins (wild-type and mutants) 
from the inclusion bodies followed by refolding. 
(37) This approach has been shown to be highly 
successful in the purification of a number of ABC 
transporters (32,38-40).  
The wild-type and mutant ECD2 proteins 
were extracted from inclusion bodies using a 
protocol, which combines the use of BugBuster 
protein extraction reagent (Novagen, Madison, 
WI) to process the insoluble fraction and yield 
purified inclusion bodies, with the method 
described by Booth et al. (32,38,41). After 
harvesting the expressed proteins, the cell pellets 
were resuspended in room temperature BugBuster 
reagent, and protease inhibitors were added. After 
incubation on ice for 30 minutes, the cell 
suspension was centrifuged to collect purified 
inclusion bodies. Following cell lysis, the pellet of 
inclusion bodies was resuspended in buffer B and 
centrifuged once more. The inclusion body 
proteins were solubilized in Buffer C. Protein 
refolding was achieved by rapid dilution in Buffer 
D. The renatured protein was sequentially dialyzed 
in Buffer E. After overnight dialysis, proteins were 
concentrated to ~0.5 mg/ml by ultrafiltration 
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(Amicon/Millipore).  Overall the inclusion body 
protein purification methodology described here 
yielded highly concentrated, purified, and 
homogeneous preparations of protein.  The yield 
of ECD2 protein was >10 mg from 4 liters of 
induced cell culture.  Purified proteins were stored 
at−80 °C until use.   
Circular Dichroism Spectropolarimetry. Spectra 
were collected on a Jasco-810 spectrapolarimeter 
(X-Ray and Structure Core Facility of 
ThomasJefferson University) using a 5 mm path 
length cell, and the temperature was maintained at 
25°C, or indicated temperature, using a Pelltier 
controlled cell holder. Spectra were the average of 
five scans collected at a speed of 10 nm min -1.  
CD spectra were analyzed using the K2D2 neural 
network based method 
(http://www.ogic.ca/projects/k2d2/), with its 
associated web server to estimate protein 
secondary structure (42-43).  
For thermal melting experiments, the 
ellipticity at 220 nm was monitored over a 
temperature range of 20-80°C, using a resolution 
of 0.2°C, a bandwidth of 1 nm, and a temperature 
gradient of 1°C min -1. Global analysis of the data 
was conducted using the PRISM program 
(GraphPad Software, Inc.).  
Steady-State Fluorescence Measurements- 
Fluorescence experiments were performed using a 
Fluorolog-2 spectrofluorometer (Jobin Yvon 
Horiba Inc., Edison, NJ), and measurements were 
made in an L-format configuration of excitation 
and emission channels.  The excitation wavelength 
was set to 295 nm to avoid excitation of either 
tyrosine or phenylalanine residues. Emission was 
scanned from 320 to 400 nm. Excitation and 
emission slits were set at 8 nm and 4 nm 
respectively. The spectra of the ECD2 polypeptide 
were measured in a 0.1 mg/ml solution in buffer E.   
Changes in steady state fluorescence were used to 
monitor interaction with all-trans and 11-cis retinal 
over a concentration range of 0-15 µM.  Titrations 
with increasing amounts of all-trans retinal were 
conducted and emission scans from 320 to 400 nm 
were taken at each concentration.  Fluorescence 
data were normalized to 0-100 arbitrary units for 
wild type ECD2 and each mutant.  A semilog plot 
of emission at 333 nm versus log [all-trans retinal] 
was fitted to the sigmoidal dose-response 
equation: 
 
 y = ymin + (ymax - ymin)/[1 + 10(logKd – X)] 
 
where y is the fluorescence intensity and x is the 
log of the all-trans retinal concentration. 
Anisotropy values were expressed as 
millianisotropy, or mA (anisotropy divided by 
1000). The standard error for the measured 
anisotropy values was ± 3 mA. An anisotropy 
reading for each titration point was taken three 
times for 10 s and averaged. The total fluorescence 
intensity did not change significantly with an 
increase in the ECD2 concentration. Therefore, 
fluorescence lifetime changes, or the scattered 
excitation light, did not affect the anisotropy 
measurements. Anisotropy, A, is defined as 
 
A  =  (Ivv - GIvh)/(Ivv + 2GIvh)               (1) 
 
where G is the instrumental correction factor for 
the fluorometer, and it is defined by,  
 
G = Ihv/Ihh  
 
where, Ivv, Ivh, Ihv, and Ihh represent the 
fluorescence signal for excitation and emission 
with the polarizers set at (0°, 0°), (0°, 90°), (90°, 
0°), and (90°, 90°), respectively. 
 
The interaction of ECD2 with all-trans retinal 
(ATR) can be represented as 
  
ECD2 + ATR ´ ECD2∑ATR (2) 
 
At equilibrium, Ka, the equilibrium association 
constant, can be given as  
 
Ka =  [ECD2∑ATR]/[ECD2][ATR]  (3) 
 
Ka = [ECD2][ATR] = [ECD2∑ATR]  (4)  
 
The fraction of the binding sites occupied can be 
represented as  
f  = [occupied binding sites]/[total binding sites]  = 
 
[ECD2∑ATR]/[ECD2] + [ECD2∑ATR] (5) 
 
Substituting for [ECD2] and rearranging the 
equation, we get 
f  = Ka(ECD2)/[1 + Ka(ECD2)]             (6) 
 
f = [ECD2]/([ECD2] + 1/Ka)              (7) 
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Similarly, the equilibrium dissociation constant Kd 
(Kd )1/Ka) can be expressed as 
 
f = [ECD2]/([ECD2] + Kd) 
 
At f = 0.5 
  Kd = [ECD2] 
 
Thus, Kd can be further defined as the protein 
concentration at which half of the sites are 
occupied when the ligand concentration is constant 
as in the present case or the ligand concentration at 
which half of the sites are occupied when the 
protein concentration is constant. Global analysis 
of the data was conducted using BIOEQS and/or 
PRISM (Graphpad Software Inc., San Diego, CA) 
programs using a monomer ligand binding model 
(44-45).  BIOEQS calculates the concentration of 
various species in the equilibrium-binding curve 
numerically using a constrained optimization 
algorithm in which the mass balance constraints 
are incorporated as Lagrange multipliers (37). The 
program then relates this species concentration 
vector to the anisotropy observed at each point in 
the titration and fits the free energy and plateau 
values by adjusting these floating parameters using  
a Marquardt-Levenberg nonlinear least squares 
algorithm (46).The Kd values, i.e., the 
concentrations of ECD2 required to bind 50% of 
the all-trans retinal, were computed using the 
equation: 
 
Y = Amin + (Amax - Amin)/(1 + 10(X0-X)napp)         (10) 
 
where Amin and Amax are the anisotropy values at 
the bottom and top plateaus, respectively, X 
represents the log of the NBD1 concentration, X0 
is the X value when the response is halfway 
between the top and the bottom, and napp is the Hill 
coefficient. 
Other Methods. Routine protein concentrations 
were determined by the method of Bradford (47) 
using bovine serum albumin as a standard, and for 
the CD/fluorescence studies using molar extension 
coefficient measurements εECD2 = 49,180. 
SDS−PAGE was carried out as described by 
Lamelli (48).  
 
RESULTS 
 
The long extracellular (EC) loops, or 
domains, are a distinctive topological feature of 
the ABCA subfamily of transporters, yet at the 
present time their structure and function remain 
unknown. Based on current models (Fig. 1), the 
ECD1 domain of ABCA4 is defined as projecting 
from TMD1 (aa 43-646) while ECD2  projects 
from TMD7 (aa 1395–1680).  We have calculated 
the grand average of hydropathicity indexes 
(GRAVY) for ECD1 and ECD2.  GRAVY 
analysis of the domains were found to be -0.294 
and -0.356 for ECD1 and ECD2, respectively 
(ProtParam; ExPASy Proteomics Server). A 
negative value corresponds to a hydrophilic 
polypeptide while a positive value corresponds to 
hydrophobic polypeptide, thus the values are 
consistent with the postulated projection of these 
domains into the aqueous environment of the 
lumen of the rod outer segment discs (Fig. 1) (49). 
Stargardt Disease Mutations Affecting Conserved 
Residues of ECD2. Several macular degenerative 
disease associated mutations map to the ECD2 
domain of ABCA4 (13,23,50-52), pointing to its 
likely significance ABCA4 function. Three 
ABCA4 mutations associated with Stargardt 
disease, W1408L, R1443H, and C1488R, were 
chosen for analysis in this study.  These missense 
mutations have been observed to occur in patients 
as simple and/or compound heterozygotes (Table 
1).  Sequence alignments of the ECD2 domains of 
ABCA4 proteins were carried out in order to 
determine the degree of conservation of these 
specific amino acid residues among the ECDs of 
several organisms. All three of the mutations 
correspond to strictly conserved amino acids in 
vertebrate ABCA4 proteins (Fig. 2).   
 Conformational Analysis of Native and Refolded 
ECD2 Polypeptides Suggest a Highly Ordered 
Structure: The structural characteristics of native 
and refolded recombinant ECD2 polypeptides 
were evaluated by comparing their CD spectra in 
the far ultra-violet region (200-250 nm).  Highly 
purified homogenous preparations of recombinant 
ECD2 protein was used for CD analysis (Fig. 3). 
Secondary structures were determined using K2D2 
neural network based analysis 
(http://www.ogic.ca/projects/k2d2/ ) (42).  
 The CD spectra of the native and refolded 
ECD2 polypeptides are presented in Fig. 4.  The 
two spectra were essentially identical and were 
typical of structurally ordered proteins, containing 
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α-helical, β-sheet, and extended coil structures. 
Both CD spectra had two minima observed at 208 
and 222 nm, characteristic of α-helical structure 
(Fig. 4). Nonlinear regression analysis of the CD 
spectra provided an estimation of ECD2 secondary 
structure; 26±3 % α-helix and 23±3% β-sheet, 
respectively (Table 2).  These results suggest that 
the structure of the refolded ECD2 polypeptide is 
essentially the same as that of the native ECD2 
protein.  We have analyzed changes in the 
conformation of ECD2 protein harboring disease 
associated mutations, W1408L, C1488R, and 
R1443H. The secondary structures of these 
proteins were then compared with that of the wild 
type polypeptide (Figs. 5 & 6).  
W1408L Mutation – The W1408L mutation has 
been reported in several studies investigating the 
ABCA4 genotype of individuals afflicted with 
Stargardt disease, fundus flavimaculatus and cone 
rod dystrophy (13,19,51).  This mutation has been 
identified in patients with and without the 
occurrence of a second ABCA4 mutation 
occurring in trans.  Alone, this mutation leads to 
late onset (30 years of age) of Stargardt disease, 
whereas, patients harboring a second ABCA4 
mutation in trans may manifest as early onset (12 
years of age) of the disease.  The Trp→Leu 
mutation represents a relatively significant 
mutation, in terms of structure and polarity.  In 
addition, the aromatic residue, with its large 
hydrophobic surface present in tryptophan, 
represents a potential “hotspot” for protein-protein 
and protein-ligand interactions and thus may alter 
the biological function of this domain (53).  The 
far-UV CD spectrum of the mutant ECD2 was 
similar to that of the wild type protein suggesting 
that this mutant maintained most of the secondary 
structural features associated with wild type 
ECD2, (Fig. 5).  Nonlinear regression analysis 
using the K2D2 algorithm of the CD spectrum 
indicated the following conformation: 23% α-
helix, 24% β-sheet, and 53% coil (Table 3).  
Analysis of the thermal melting of ECD2 
protein as demonstrated that the ellipticity 
measured at 220 nm increased with increase in 
temperature, consistent with what would be 
expected to accompany protein unfolding in a α-
helix to coil transition (Fig. 6A).  In the 
temperature range of 20°C to 80°C, the plot for the 
wild-type ECD2 protein fitted well to a sigmodial 
curve (Fig. 6A inset) and the Tm was 49.8°C 
(Table 3).  The thermal melting profile of the 
W1408L is shown in Fig. 6B.  This mutant 
appeared more resistant to thermal denaturation 
than wtECD2, indicated by a Tm of 57.1°C (Table 
3). Therefore, CD and thermal melting 
experiments suggest that the wild type and mutant 
polypeptides have relatively similar secondary 
structure compositions at 25°C, although a higher 
Tm may indicate a decreased structural flexibility.   
C1488R Mutation - The C1488R mutation has 
been identified as a Stargardt disease-linked 
mutation in individuals of Northern and Central 
European ancestry (13,23,50).  This mutation has 
been reported to occur in the ABCA4 gene as an 
individual heterozygous mutation as well as in 
trans with G863A mutation. This mutation 
represents a chemically significant substitution of 
a basic residue for a strictly conserved cysteine 
residue.  The far-UV CD spectrum of C1488R 
mutant at 25°C is presented in Fig. 5.  Nonlinear 
regression analysis of the CD spectrum using 
K2D2 algorithm indicated the following 
conformation: 20% α-helix, 27% β-sheet, and 
53% coil (Table 3). Although a dramatic change in 
the overall CD spectrum of the protein was not 
observed, the substitution resulted in a significant 
alteration in the Tm, from 49.8°C to 66.7°C, as 
determined by thermal denaturation CD spectra 
(Fig. 6C & Table 3).  The sudden increase in Tm of 
this mutant is not simply an indication of structural 
stability; rather it may signify loss of flexibility in 
the structure of this domain.  A certain degree of 
structural flexibility may be important for its 
function.  Introduction of the charged arginine 
residue at this location could lead to abnormal salt 
bridge formation, which would support this 
hypothesis.   
R1443H Mutation - The R1443H mutation has 
been identified in individuals with Stargardt 
disease and appears to occur in those with 
Northern European as well as East Indian ancestry 
(23,54).  From a biochemical perspective, 
Arg→His represents a change from a highly basic 
residue, to an almost neutral residue, and thus 
represents a potentially significant change in terms 
of physico-chemical properties.  The CD spectrum 
of this mutant was significantly altered (Fig. 5). 
Major shifts in the CD spectral minima at 208 and 
220 nm for R1443H were observed at 25°C, 
consistent with a helix-coil transition concomitant 
7 
 
with a significant change of overall secondary 
structure (Fig. 5).  Analysis of the spectra using 
the K2D2 method shows that the polypeptide had 
relatively little α-helical content, ~11%, as 
compared to 25% in wild-type ECD2 (Table 3).  
Comparing the spectra of the native and heat-
denatured states of the R1443H mutant, it appears 
that the heat-induced alterations of the secondary 
structure elements over the temperature range of 
20-80○C were small. It is likely that the absence of 
a sequential loss of structure with temperature may 
simply reflect the lack of α-helical structure of 
R1443H relative to wtECD2. 
The ECD2 Domain Specifically Interacts with all-
trans Retinal. ABCA4 is believed to function 
primarily in the transport and recycling of all-trans 
retinal produced in the ROS discs during the visual 
transduction cycle (55). The ECD2 domain may 
have a number of different roles in the function of 
ABCA4.  Our hypothesis is that it may play a role 
in the interaction of ABCA4 with retinal.  In this 
study, we had the opportunity to study the ECD2 
domain separate from the rest of the ABCA4 
molecule.  Therefore, we have utilized this model 
system to examine ECD2 interaction with retinal.  
We observed a significant change in the 
tryptophan fluorescence emission spectrum of 
ECD2 protein upon retinal addition and the change 
was dose-dependent. We have used this as a 
fluorescence-based assay to investigate interaction 
of retinal derivatives with the ECD2 domain. 
  Inspection of the primary sequence of 
ECD2 shows that seven tryptophan residues are 
present in this domain. These residues provide an 
indicator of their surroundings as their 
fluorescence emission is attenuated in response to 
a shift from hydrophobic to hydrophilic 
environments as a consequence of conformational 
change (56). Changes in protein confirmation as a 
result of ligand binding or amino acid substitutions 
can thus be monitored.  The fluorescence spectra 
of wild-type ECD2 polypeptide was collected at 
25°C as described in “Experimental Procedures” 
in the absence and presence of all-trans retinal 
over a concentration range of 0-15 µM. ECD2 
displayed a strong emission maximum at 335 nm, 
characteristic of tryptophan residues in a 
hydrophobic environment (Fig 7A). Upon titration 
with all-trans retinal, the tryptophan emission 
maxima at 335 nm decreased in a dose-dependent 
manner and appeared to saturate at a concentration 
of 10 µM retinal (Fig 7A).  We have examined 
fluorescence properties of all-trans retinal in the 
300-400 nm range in order to examine the 
possibilities of inner-filter effects or fluorescence 
resonance energy transfer (FRET).  All-trans 
retinal did not show any detectable absorption or 
emission in this wavelength range.  These results 
indicated (1) the ECD2 polypeptide bound all-
trans retinal, and (2) the binding accompanied 
concomitant conformational changes and/or 
changes in tryptophan environment.  A semi-log 
plot of the attenuated fluorescence intensities at 
different all-trans retinal concentrations is shown 
in Fig. 8.  The plot was fitted by non-linear 
regression using PRISM 5.0 to sigmoidal dose-
response as detailed in “Experimental 
Procedures”.  The Kd (or EC50) was determined to 
be 1.3 ± 1.1 x 10-7  M for wild-type ECD2 protein.   
  In contrast to all-trans retinal, 11-cis 
retinal had only minor effects on the tryptophan 
emission spectrum of ECD2 in the same 
concentration range (Fig. 9). Although some 
changes with increasing concentrations of 11-cis 
retinal were observed, perturbations in the 
emission spectra were far less significant than that 
observed with all-trans retinal.  Thus, either the 
binding of 11-cis retinal was far weaker than all-
trans retinal or the binding of 11-cis retinal did not 
elicit the same extent of conformational changes 
as all-trans retinal binding.  In either case, the 
effects of all-trans retinal are distinct from 11-cis 
retinal.  
Our results indicated that all-trans retinal 
elicited a significant effect on the tryptophan 
emission spectrum of wild-type ECD2 protein.  
Therefore, we examined its effect on the 
tryptophan emission spectra of the three Stargardt 
mutants (Figs. 7B-D).  Varying degrees of 
quenching of their intrinsic tryptophan 
fluorescence was observed in the presence of all-
trans retinal, suggesting altered modes of binding 
in the mutants. With both W1408L and C1488R, 
attenuation of tryptophan fluorescence emission 
was observed with increasing concentrations of 
all-trans retinal (Fig. 7 B&C), albeit significantly 
diminished compared to that observed with the 
wild-type ECD2 (Figs. 7A).  On the other hand, 
mutant Arg1443His displayed little change in 
tryptophan fluorescence spectra in the presence of 
all-trans retinal, which would indicate that this 
mutant did not undergo all-trans retinal binding 
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and/or associated conformational change.  
Quantitative analysis of all-trans retinal binding 
with these three ECD2 mutants is shown in Fig. 8.  
The Kd values for W1408L and C1488R were 8.1 
x 10-7 M and 6.7 x 10-7 M, respectively.  
Compared to the wild-type ECD2, the binding of 
all-trans retinal by these mutants was significantly 
weaker.  With R1433H mutant, the Kd value could 
not be determined and was estimated it to be >30 
µM.    
Fluorescence Anisotropy Analysis of the 
Influence of the R1433H Mutation on all-trans 
Retinal Binding.  Intrinsic tryptophan fluorescence 
analyses in the presence of all-trans retinal were 
indicative of conformational change, which in turn 
was suggestive of ECD2 protein-ligand 
interaction.  Thus it was of interest to demonstrate 
direct binding of all-trans retinal to this domain.  
We have utilized fluorescence anisotropy analysis 
to evaluate all-trans retinal binding. Fluorescence 
anisotropy is normally used for direct 
measurements of ligand binding by determining 
the concentrations of bound and free ligand in 
solution due to differences in anisotropy values 
between bound and free ligand (44-45,57-58). 
Therefore, true equilibrium measurements are 
possible in this procedure without needing to 
isolate the protein•ligand complex from the free 
ligand.  Due to its structural features, all-trans 
retinal is a natural fluorophore.  
In order to determine the appropriate 
emission/excitation parameters to use in 
anisotropy studies, emission spectra of 100 nM all-
trans retinal following excitation at 310 nm were 
collected over the range 370-570 nm.  All-trans 
retinal displayed an emission maximum at 430 nm 
(Fig. 10A) and thus anisotropy was measured 
using 100 nM all-trans retinal with the 
wavelengths set at 310 nm for excitation and 430 
nm for emission. The fluorescence anisotropy 
changes with ECD2 protein concentration are 
shown in Fig. 10B. For wild-type ECD2 protein, a 
sigmoidal semilog plot was obtained indicating 
equilibrium saturation binding of all-trans retinal 
by this protein.  Clearly, the binding of the 
R1433H mutant was impaired relative to that of 
the wild type protein, as indicated by its inability 
to achieve saturation.  The plots, shown in Fig. 
10B, were generated by nonlinear regression 
analysis of the data using commercial graphing 
software (PRISM, GraphPad Inc.). The binding 
parameters were determined from the fluorescence 
anisotropy data by equilibrium binding analysis 
and fitted to Equation 3, using the BIOEQS 
program (45). This nonlinear regression analysis 
gave a dissociation constant (KD) for ECD2 of 4.0 
± 1.3 x 10-7 M for the wild type protein.    
 
DISCUSSION 
 
 The ABCA4 protein is an essential 
component of the visual signal transduction cycle 
in rod and cone cells of vertebrate retina. 
Currently no direct assay for measurement of 
ABCA4 mediated transport is available.  However, 
ABCA4 knock-out mice, as well as patients 
harboring mutations in ABCA4, display 
accumulation of all-trans retinal and N-
retinylidene-PE in rod photoreceptor disc 
membranes, providing evidence that ABCA4 
protein functions in the recycling of all-trans 
retinal (20,59-60). ABCA4 contains two extended 
extracellular loops that are evolutionarily 
conserved but lack any apparent function. Genetic 
studies involving patients with inherited macular 
degenerations, demonstrate mutations in these 
domains clearly impair ABCA4 transporter 
function, thereby establishing important role(s) of 
the ECDs (19,23,50-51,54).  
The Second Extracellular Domain of ABCA4 
Possesses a Highly Ordered and Stable 
Conformation. In order to delineate its role in 
ABCA4 transporter function, we first explored the 
structure and conformational features of the ECD2 
domain and alterations due to disease-associated 
mutations.  Analysis of the CD spectral data using 
the K2D2 method indicated that the wild type 
polypeptide possessed a highly ordered structure 
that has a reasonably high α-helical content in 
addition to β-sheet and extended structures. 
Depending on the mutation, ECD2 protein 
conformation changed only slightly or very 
drastically. Thus, CD analysis provided a method 
for monitoring conformational changes due to 
macular degenerative disease associated 
mutations.  
 Unfortunately despite an intensive search, 
very little collective information correlating the 
severity and age of onset with a given mutation is 
available, making it difficult for us to correlate the 
observed structural defects with a given clinical 
phenotype.    
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Influence of Stargardt Disease Associated 
Mutations on ECD2 Domain Secondary Structure: 
Of the three mutants examined here, the R1443H 
mutation appeared to be the most severe in terms 
of its influence on the secondary structure of 
ECD2. As a consequence of this mutation, the 
ECD2 polypeptide appeared to lose the majority of 
its α-helical secondary structure (Fig. 5).  Very 
little change was observed in the protein’s 
structure in response to temperature (Fig. 6D), 
suggesting that the polypeptide was highly 
disordered. A minimal change in the CD spectrum 
was observed with the W1409L mutation.  This 
mutant appeared to have secondary structural 
parameters which were comparable to that of the 
wild type ECD2 polypeptide.  In addition, only a 
small increase in Tm was observed from the 
thermal melting curves.  This small increase may 
be due to the decrease in relative hydrophobicity 
associated with the WL mutation, such as that 
described by Kotik and coworkers in their studies 
which examining the role of tryptophan residues in 
the structural and thermal stability of lactate 
dehydrogenase (61).   The C1488R mutation 
appeared to be intermediate in nature with respect 
to its influence on the ECD2 structure.  Based on 
the CD analysis of the protein, it appeared to have 
lower α-helix content.  Interestingly, a major 
increase in the Tm obtained from the thermal 
melting profile of the CD spectra was observed. 
The substitution of a charged residue, arginine for 
cysteine, may provide enhanced thermal stability 
to the structure, perhaps through ionic interactions.  
Liao and coworkers report similar increases in Tm 
upon introduction of charged residues into porcine 
αβ-crystallin (62). ECD2 Domain Interacts 
Specifically with all-trans Retinal: Several lines of 
investigation support the hypothesis that all-trans 
retinal, the product of the visual transduction 
cycle, is the substrate of ABCA4 (63-65).  
Physiologically, studies of ABCA4 knockout mice 
show elevated levels of all-trans retinal and the 
protonated Schiff’s base, N-retinylidene-PE, as 
well as the di-retinal pyridinium compound A2E 
in the retinal pigment epithelium (65-67).  
Together these studies strongly support all-trans 
retinal as the substrate for ABCA4. However, at 
present no assay for ATP dependent transport by 
ABCA4 has been developed and which region of 
the ABCA4 molecule interacts specifically with 
the substrate remains to be identified.   
Using tryptophan fluorescence emission 
spectrum, we have investigated the binding of 
ECD2 domain to retinal, and examined how this 
binding is affected in disease associated mutants.  
When all-trans retinal was added to ECD2 
polypeptide, dose-dependent attenuation of its 
tryptophan fluorescence was observed (Fig. 7). 
Titration with all-trans retinal was used to 
evaluate the binding quantitatively, and the ECD2 
polypeptide bound all-trans retinal with 
reasonably high affinity, Kd, app of 1.3 x 10-7 M 
(Fig. 8 and Table 3).  The binding appeared highly 
specific as attenuation of tryptophan fluorescence 
by 11-cis retinal was significantly lower (Fig 9).  
The affinity of interaction for all-trans retinal 
observed in our experimental system is 
approximately ~30-fold higher than that 
previously reported by Beharry et al. (64).  Using 
fluorescence anisotropy we were able to 
demonstrate direct interaction of the ECD2 
polypeptide and quantitate its interaction.  The KD 
of 4 ± 1.3 X 10-7 is approximately 2-fold higher 
than that derived from the intrinsic tryptophan 
fluorescence.  This small difference may be 
attributed to the fact that the two approaches are 
assessing retinal interaction through the 
measurement of two different parameters: one 
examines the change in ECD2 protein structure as 
using tryptophan environment as a reporter, the 
other approach measuring the fluorescence 
anisotropy of all-trans retinal itself. 
The locations of the seven tryptophan 
residues are indicated on the multiple sequence 
alignment shown in Figure 2.  These residues are 
strictly conserved and are distributed across the 
domain. The emission maxima and quantum yields 
of tryptophan residues vary widely between 
proteins and can be a function of protein structure 
(37{Lugo, 2009 #4375{Lakowicz, 2006 #1086)}. 
A given protein conformation may contribute to 
specific protein environments that quench a given 
tryptophan residue or residues.     All-trans retinal 
is a relatively large, hydrophobic molecule and its 
binding site would need to be hydrophobic as well.  
Indeed, studies examining retinoid binding 
properties of the nematode ABA-1 allergen 
protein, describe the major structural role of 
tryptophan in providing a hydrophobic binding site 
for the ligand (68).  A possible explanation for the 
observed decrease in fluorescence would be that 
the ECD2 domain undergoes a conformational 
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change during retinal binding, in order to create a 
hydrophobic pocket.  The conformational change 
causes a change in the environment of the 
tryptophan residues, thereby leading to the 
observed decrease in fluorescence. This  
 These studies indicate that the ECD2 
domain is involved in binding all-trans retinal in 
its transport across the ROS disc membrane.   
ECD2 may also be involved in the transport of 
retinal derivatives, such as N-retinylidine-
phosphatidyl ethanolamine, since the Shiff’s base 
present in these compounds is formed from the 
aldehyde functional group of all-trans retinal. 
Influence of Stargardt Disease Associated 
Mutations on ECD2 Interaction with all-trans 
Retinal: To date the biochemical observables 
measured for mutant ABCA4 proteins have been 
restricted to ATP binding and hydrolysis; protein 
localization of heterologously expressed protein in 
cell culture, and interaction of the nucleotide 
binding domains (32,67,69-72).  All mutants 
investigated demonstrated decreases in their 
affinity of interaction with all-trans retinal, based 
on their ability to attenuate intrinsic tryptophan 
fluorescence (Figs.  7 & 8). In the case of mutant 
R1443H a large decrease in the binding affinity 
was observed, with a >250-fold increase in Kd 
(Fig. 8 and Table 3).  Less dramatic changes were 
seen with the other mutants investigated in this 
study; with a 5-8-fold increase in Kd for W1408L 
and C1488R respectively. With mutant R1443H,  
apparent lack of interaction with all-trans retinal 
was observed. Direct analysis of mutant R1433H 
interaction confirmed impairment of all-trans 
retinal binding by this mutant, as shown by the 
inability to achieve saturation (Fig. 10B).  
Interestingly, the functional alterations in all-trans 
retinal interaction were mirrored by the structural 
alterations in this domain as determined by CD 
spectroscopic analysis of their conformations. The 
conformation of R1443H was strikingly different 
from that of wt ECD2, and appeared refractory to 
changes in temperature.  It is likely that its 
inability to interact with all-trans retinal has a 
basis in its abnormal structural features.  Likewise, 
the relatively moderate structural changes of 
W1408L and C1488R also correlated with more 
moderate changes in interaction with all-trans 
retinal as compared to the wild type ECD2. 
This report demonstrates that the ECD2 
domain of ABCA4 has a highly ordered and stable 
secondary structure, which appears to undergo 
conformational change in response to its specific 
interaction with its putative substrate all-trans 
retinal.  Disease associated mutations in this 
domain were observed to influence the secondary 
structure and all-trans retinal binding affinity. 
Further studies of each of the ABCA4 domains are 
required to elucidate the mechanism of retinal 
transport by this complex and physiologically 
important ABC transporter. 
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FIGURE LEGENDS 
 
Fig. 1. Predicted Structural Organization of ABCA4 and Its Domains.  Pictorial representation 
showing the cytoplasmic, extracellular and transmembrane domains of ABCA4 protein.  The 
domains were defined based on current topological models of ABCA4 (24), and are as follows: 
NDB1 aa 854 - 1375, NBD2 aa 1898-2273, ECD1 aa 62-646 and ECD2 aa 1395-1680.  
 
Fig. 2.  Sequence Alignment of ECD2 Domains of ABCA4 Proteins Derived from Several 
Vertebrate Species.  The amino acid sequences of several vertebrate organisms were obtained 
from NCBI; H. sapiens (human), M. faccicularis (crab eating macaque), B. taurus (bovine), C. 
familiaris (dog), M. musculus (mouse) and X. laveis (African clawed frog), and were aligned 
using ClustalW.  The amino acid residue number for each protein is indicated at the beginning of 
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each sequence.  The alignment is color coded to indicate chemical characteristics of a given 
amino acid: red, basic; blue hydrophobic; green, hydrophilic; orange, neutral, pink, acidic, and 
light green, proline.  Missense mutations examined in this study are enclosed by boxes. 
 
Fig. 3.  Purification of ABCA4-ECD2 Protein. (A) Overexpression of ABCA4-ECD2 
Polypeptide.  SDS-PAGE analysis of the overexpressed ECD2 polypeptide in E. coli. Expression 
of the recombinant protein was carried out as described in “Methods” in the presence of 0.25 mM 
IPTG. Equal amounts of cells before and after induction were analyzed. Lane 1, protein 
molecular mass standard; lane 2, uninduced RIPL (DE3)/pET30b ECD2 cell lysate; and lane 3, 
cell lysate from IPTG induced RIPL (DE3)/pET30b ECD2. (B) ECD2 Polypeptide Purified by S-
Protein Agarose Chromatography.  SDS-PAGE of S-protein agarose purification of ECD2.  An 
aliquot (corresponding to 10 µg) of purified ECD2 was analyzed on a 5 →18% SDS PAGE gel 
which was stained with Coomassie Blue R250 following electrophoresis. (C) ECD2 Wild Type 
and Mutant Purified Refolded Polypeptides.  Approximately 4.5 µg of the respective purified, 
refolded protein was loaded onto a 5–18% SDS-PAGE, which was stained with Coomassie Blue 
R-250 following electrophoresis. As shown the ABCA4-ECD2 protein migrated with predicted 
molecular mass of ~34 kDa. 
 
Fig. 4. Circular Dichroism Spectra of Native and Refolded ABCA4-ECD2 Polypeptides. 
Comparative far-UV (200-250 nm) CD spectra of ECD2 from S-tag agarose and refolding-based 
purifications.  The concentration of ECD2 polypeptide was 10 µM in 10 mM NaPO4, pH 7.5, 100 
mM NaCl.  The spectra were acquired with a 5 mm path length cuvette, at 25°C; scans were 
collected five times and averaged.  Buffer spectra were always subtracted.  Native-S-protein 
agarose chromatography (dashed line), refolded (solid line). 
 
Fig. 5. Circular Dichroism Spectra of Wild Type and Mutant ABCA4-ECD2 Polypeptides. CD 
spectra were collected from highly purified homogenous preparations of recombinant wild type 
and mutant ECD2 polypeptides.  Far-UV (200-250 nm) CD spectra were acquired with a 5 mm 
path length cuvette.  The concentration of ECD2 polypeptides were 10 µM in 10 mM KPO4, pH 
7.5, 100 mM NaCl.  The spectra were acquired with a 5 mm path length cuvette, at 25°C; scans 
were collected five times and averaged.  Buffer spectra were always subtracted. 
 
Fig. 6.  Circular Dichroism Spectra of Wild Type and Mutant ABCA4-ECD2 Polypeptides as a 
Function of Temperature.  CD spectra were acquired (200-250 nm) over the range of 20-80°C, at 
10°C increments, using a resolution of 0.2°C. The concentration of ECD2 wild type and mutant 
polypeptides were 10 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl.  The spectra were acquired 
with a 5 mm path length cuvette, at 25°C; scans were collected five times and averaged.  Buffer 
spectra were always subtracted. (A) wild type ECD2; inset: ellipticity at 220 nm was monitored 
over the range of 20-80°C and the Tm was determined from the inflection points of data fitted to 
sigmodial curve.; (B) W1408L; (C) C1488R , and (D) R1443H.   
 
Fig. 7.  Tryptophan Fluorescence Intensity of Wild-Type and Mutant ABCA4-ECD2 
Polypeptides in the Presence of all-trans Retinal.  Fluorescence spectra of wild-type and mutant 
ECD2 polypeptides were collected at 25°C in the presence of increasing amounts of all-trans 
retinal over the concentration range 0-15 µM as indicated.  The concentration of ECD2 
polypeptide was 3 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl. The scans were conducted in 
triplicate and the data were analyzed by least-squares regression analysis using Graph Pad 
PRISM software. 
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Fig. 8.  Ligand Binding Analysis by Monitoring Changes in Intrinsic Tryptophan Fluorescence in 
the Presence of all-trans Retinal. Data obtained from the fluorescence spectra of wild-type and 
mutant ECD2 polypeptides described in Figure 7 were analyzed in terms of percent change in 
intensity versus log of the all-trans retinal concentration.  () ECD2 WT; () R1443H; () 
W1408L; () C1488R.  
 
Fig. 9.  Tryptophan Fluorescence Intensity of Wild-Type ECD2 in the Presence of 11-cis Retinal.  
Fluorescence spectra of wild-type ECD2 polypeptide were collected at 25°C in the presence of 
increasing amounts of 11-cis retinal over the concentration range 0-10 µM as indicated.  The 
concentration of ECD2 polypeptide was 3 µM in 10 mM NaPO4, pH 7.5, 100 mM NaCl. The 
scans were conducted in triplicate and the data were analyzed by least-squares regression analysis 
using Graph Pad PRISM software. 
 
Fig. 9.  Fluorescence Anisotropy Analysis of ECD2 proteins with the all-trans Retinal. (A) 
Emission spectrum of 100 nM all-trans retinal (ATR).  Excitation was 310 nm and emission was 
scanned over a range of 370 to 570 nm (B) Anisotropy titrations using wild-type ECD2 () and  
the R1433H mutant ().   The titrations were carried out as described under “Materials and 
Methods.” Fluorescence anisotropy measurements were collected for ATR•ECD2 protein 
samples formed by the stepwise addition of ECD2 protein to 100 nM ATR.  All samples were 
incubated at room for 2–3 min with constant stirring before taking anisotropy measures. The data 
were fitted with BIOEQS using a simple binding model (monomer) for all-trans retinal binding to 
wild-type and R1433H proteins NBD1 proteins. 
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Table 1: Stargardt Disease Associated Mutations Occurring in the ECD2 Domain 
Investigated in this Study. 
 
 
 
Mutation Base Change Mutagenesis Primer 
R1443H CGC4328CAC 5'-CAGGCTTTGGCAACCACTGAAGGAAGGGTGGCTTC-3' 
W1408L TGG4221TTG 5'-ACCCTTCACCCCTTGATATGGGCAGCAGTACACCTTC-3' 
C1488R TGC4462CGC 5'-AACCCTTCACCATCCCGCAGGTGCAGCACCAGGGAGAAG-3' 
17 
 
 
Table 2: Summary of the Secondary Structure for ECD2 Polypeptide. 
 
      Secondary Stucture 
 
ECD2 protein 
α-helix β-sheet Extended-coil 
Affinity Purified 0.27 0.20 0.53 
Refolded 0.25 0.20 0.55 
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Table 3: Summary of Secondary Structure Analysis and Binding Constants for the ABCA4-
ECD2 WT and Mutant Polypeptides Based on CD Data Analyzed by K2D2 Method (42-43). 
 
Genotype α-helix β-sheet Random coil Tm (°C) Kd (M) 
Wild-type 0.25 0.20 0.55 49.7 1.3 x 10-7 
R1433H 0.11 0.39 0.50 n.d. n.d. 
W1408L 0.23 0.24 0.53 57.1 8.1 x 10-7 
C1488R 0.20 0.27 0.53 66.7 6.7 x 10-7 
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